UNIVERSI
TÄ
TS-
BIBLIOTHEK
P
ADERBORN
Anmelden
Menü
Menü
Start
Hilfe
Blog
Weitere Dienste
Neuerwerbungslisten
Fachsystematik Bücher
Erwerbungsvorschlag
Bestellung aus dem Magazin
Fernleihe
Einstellungen
Sprache
Deutsch
Deutsch
Englisch
Farbschema
Hell
Dunkel
Automatisch
Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist
gegebenenfalls
nur via VPN oder Shibboleth (DFN-AAI) möglich.
mehr Informationen...
Universitätsbibliothek
Katalog
Suche
Details
Zur Ergebnisliste
Ergebnis 26 von 47
Datensatz exportieren als...
BibTeX
Using fluorodeoxythymidine to monitor anti-EGFR inhibitor therapy in squamous cell carcinoma xenografts
Head & neck, 2008-06, Vol.30 (6), p.790-799
Atkinson, David M.
Clarke, Michelle J.
Mladek, Ann C.
Carlson, Brett L.
Trump, David P.
Jacobson, Mark S.
Kemp, Brad J.
Lowe, Val J.
Sarkaria, Jann N.
2008
Volltextzugriff (PDF)
Details
Autor(en) / Beteiligte
Atkinson, David M.
Clarke, Michelle J.
Mladek, Ann C.
Carlson, Brett L.
Trump, David P.
Jacobson, Mark S.
Kemp, Brad J.
Lowe, Val J.
Sarkaria, Jann N.
Titel
Using fluorodeoxythymidine to monitor anti-EGFR inhibitor therapy in squamous cell carcinoma xenografts
Ist Teil von
Head & neck, 2008-06, Vol.30 (6), p.790-799
Ort / Verlag
Hoboken: Wiley Subscription Services, Inc., A Wiley Company
Erscheinungsjahr
2008
Quelle
Wiley Online Library Journals【Remote access available】
Beschreibungen/Notizen
Background 3′‐18F‐fluoro‐3′‐deoxy‐fluorothymidine (18F‐FLT), a nucleoside analog, could monitor effects of molecularly targeted therapeutics on tumor proliferation. Methods We tested whether 18F‐FLT positron emission tomography (PET) uptake changes are associated with antitumor effects of erlotinib in A431 xenografts or cetuximab in SCC1 xenografts. Results Compared with pretreatment FLT PET scans, 3 days of erlotinib in A431 reduced the standardized uptake value (SUV) by 18%, whereas placebo increased SUV by 1% (p = .005). One week of cetuximab in SCC1 reduced SUV by 62%, whereas placebo reduced SUV by 16% (p = .005). FLT uptake suppression following anti–epidermal growth factor receptor (EGFR) treatment was associated with reduced tumor thymidine kinase‐1 (TK1) activity. In vitro TK1 knockdown studies confirmed the importance of TK1 activity on intracellular FLT accumulation suppression. Conclusions 18F‐FLT PET imaging detects tumor responses to EGFR‐inhibitors within days of starting therapy. This technique may identify patients likely to benefit from EGFR‐inhibitors early in their treatment course. © 2008 Wiley Periodicals, Inc. Head Neck, 2008
Sprache
Englisch
Identifikatoren
ISSN: 1043-3074
eISSN: 1097-0347
DOI: 10.1002/hed.20770
Titel-ID: cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3942889
Format
–
Schlagworte
Animals
,
anti-EGFR inhibitor therapy
,
Antibodies, Monoclonal - therapeutic use
,
Antibodies, Monoclonal, Humanized
,
Antineoplastic Agents - therapeutic use
,
Biological and medical sciences
,
Carcinoma, Squamous Cell - diagnostic imaging
,
Carcinoma, Squamous Cell - drug therapy
,
Cetuximab
,
Dermatology
,
Dideoxynucleosides
,
Disease Models, Animal
,
erlotinib
,
Erlotinib Hydrochloride
,
Female
,
Fluorine Radioisotopes
,
fluorodeoxythymidine (FLT)
,
Head and Neck Neoplasms - diagnostic imaging
,
Head and Neck Neoplasms - drug therapy
,
Humans
,
Medical sciences
,
Mice
,
Mice, Nude
,
Neoplasm Transplantation
,
Otorhinolaryngology. Stomatology
,
Positron-Emission Tomography
,
Protein Kinase Inhibitors - therapeutic use
,
Quinazolines - therapeutic use
,
Receptor, Epidermal Growth Factor - antagonists & inhibitors
,
squamous cell carcinoma xenografts
,
Tumors of the skin and soft tissue. Premalignant lesions
Weiterführende Literatur
Empfehlungen zum selben Thema automatisch vorgeschlagen von
bX